Does Deep Brain Stimulation of the Subthalamic Nucleus Prolong Survival in Parkinson's Disease? by Contarino, M.F. et al.
1 
 
Does Deep Brain Stimulation of the subthalamic nucleus prolong survival in 
Parkinson’s disease? 
 
M.F. Contarino, MD PhD1,2, J. Marinus1, PhD, J.J. van Hilten, MD PhD1 
1. Department of Neurology, Leiden University Medical Centre, Leiden, The 
Netherlands. 
2. Department of Neurology, Haga Teaching Hospital, The Hague, The Netherlands. 
 
 
Corresponding authors:  
*M.F. Contarino, Department of Neurology, Leiden University Medical Center, Albinusdreef 
2, 2333 ZA Leiden, The Netherlands (tel.: +31 71 526 3964; fax: +31 71 524 8253; e-
mail: m.f.contarino@lumc.nl).  
*J.J. van Hilten, Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 
2333 ZA Leiden, The Netherlands (tel.: +31 71 526 2134; fax: +31 71 524 8253; e-
mail: j.j.van_hilten@lumc.nl).  
 
Manuscript word count: 1393  
 
Running title: Does DBS prolong survival in PD? 
 
Keywords: Deep brain stimulation, survival, Parkinson’s disease 
 
Financial disclosure / conflict of interest:  
MFC: Advisory board: Medtronic, Boston Scientific. Independent consultant for Medtronic 
for research and educational issues. Speaking fees: Novartis Pharma BV (Jan 2017 – CME 
activity). Received a grant from the Stichting Parkinson Fonds. JM: None. JJvH: None. The 
DBS center of the Haga Teaching Hospital/LUMC received compensation for DBS training 
activities and an unrestricted educational grant from Medtronic. 





Parkinson’s disease (PD) is associated with increased mortality, which has not changed 
much after the introduction of levodopa.1-3 According to a recent study, however, mortality 
rates in idiopathic PD are increased only moderately, with a reduction in life expectancy of 
about one year as compared to the general population (hazard ratio [HR] = 1.75; 95% CI: 
1.39-2.21).4 
Over the last decades, Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) has 
emerged as an effective treatment for drug-resistant resting tremor and disabling drug-
induced motor complications in patients with PD. Growing data show an improvement of 
motor symptoms and quality of life in PD patients over a period of up to five years after 
DBS.5 The few available studies with longer follow-up periods (8-10 years), show a persistent 
effect on dopaminergic motor symptoms, although axial symptoms (gait, speech, postural 
stability) and non-motor symptoms (e.g. cognitive function) deteriorate. Data on quality of 
life in follow up above 5 years are scanty.6-11  
 
It is hitherto still unclear whether STN DBS improves survival of patients with PD.  
Several studies reported on survival of PD patients after DBS,10, 12, 13 but only three studies 
used a control group and are therefore potentially informative of a survival difference 
between patients who did or did not undergo STN DBS.14-16 One of these studies found no 
significant difference in survival in the DBS group in comparison with a PD control group 
derived from a population-based control series.14 Due to the study design and inclusion 
criteria used, biases in favour of the control group cannot be excluded. Indeed, patients 
were included if they were still alive after the inclusion period of four years and had 
completed two motor examinations, which led to the exclusion of 81 patients who had 
already died in the control group, as opposed to only two patients in the DBS group. In 
addition, important data such as disease duration at baseline or age at onset were not 
reported. Two other studies reported longer survival in the DBS-group.15, 16 In one study, the 
control group included patients who were deemed eligible for surgery but decided to 
continue medical treatment.15 The two patient groups did not show significant differences 
at baseline concerning age, gender, ethnicity, disease duration, amount of medication, or 
pre-existing diagnosis of depression. Even after adjusting for potential confounding factors, 
patients undergoing STN-DBS showed significantly longer survival (HR=0.29, 95% CI: 0.13-
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0.64, p=0.002) and were significantly less likely to be admitted to a residential care home 
(OR=0.1, 95% CI: 0.0-0.3, p<0.001) than those managed purely medically. Although this is a 
convincing study, some uncertainties remain because the control group was relatively small 
(41 patients), and the fact that patients in the control group refused surgery could 
theoretically by itself introduce some bias. In addition, relevant information on comorbidity, 
baseline UPDRS score and cognition was not available. The most recent study16 involved a 
large multicentre cohort study of 611 veterans with PD who received DBS and were 
retrospectively propensity-score matched to a cohort of 611 veterans with PD who were 
only medically managed. The results showed a survival advantage of approximately 7.6 
months for patients with DBS (2291 vs 2063 days; HR=0.69, 95% CI: 0.56-0.85). It must be 
noted that, comparable to other methods aiming to resolve confounding problems in causal 
inference, the propensity score approach has its limitations.17 The justification of using a 
propensity score approach is evidently dependent on the availability of information on the 
individual and contextual confounders. Unfortunately, the authors had no information on 
age at onset, disease duration and disease stage at the index date. More importantly, they 
had also no information on the severity of motor (including postural instability, freezing, and 
speech) and non-motor symptoms (including cognitive function and psychiatric symptoms). 
Most of these symptoms that are often considered as exclusion criteria for DBS and 
negatively affect survival18, 19 will inevitably occur more frequently in the control group, thus 
favorably affecting survival in the DBS cohort. In addition, while, on the one hand, DBS may 
have been offered to patients in more advanced stages of the disease (with negative 
consequences for survival of the DBS cohort), on the other hand, surgery is usually withheld 
to patients who are too advanced in their disease to benefit from the procedure or have 
other comorbidities (with negative consequences for survival of the medically managed 
cohort). 
Despite the use of large cohorts and attempts to match groups properly, it is of note that 
the selection procedure for DBS involves some intrinsic biases that cannot be avoided, if not 
in a randomized controlled trial of sufficient sample size, in which patients are recruited 
from the same population, in the same time period, and where they are followed up 
sufficiently long. Such a trial in patients with advanced PD is probably unethical and not 
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feasible, given the demonstrated superiority of DBS in improving quality of life of selected 
patients as compared to best medical treatment, at least in the short to medium term. 
Nevertheless, although the evidence thus far is not fully conclusive, the data that are 
available seem to point to some increased survival in favour of DBS. This survival benefit 
may potentially be attributed to improved motor control in DBS patients, which may in turn 
positively influence general health, for example by restoration of weight loss, better 
swallowing and respiratory functions, and more efficient personal care. The results of one 
study indeed showed that a significantly lower proportion of DBS patients died of 
respiratory causes in comparison with medically managed patients,15 although this 
difference was not found in another study.16 
Alternatively, increased survival after STN DBS might also point to a direct effect of 
stimulation on the disease course. The suggestion of neuroprotection has been proposed 
since the dawn of STN DBS therapy, based on the idea that the reduced glutamatergic 
cytotoxicity induced by STN neuromodulation, would favourably affect 
neurodegeneration.20 However, the experimental papers supporting this hypothesis were 
based on the use of artificial animal models that in many ways differs from the degenerative 
disease affecting patients with PD.20-22 So far, studies in PD patients have failed to 
convincingly demonstrate any neuroprotective effect of DBS. For example, a prospective 
study with serial functional neuroimaging (PET),23 showed annual progression rates in the 
caudate and putamen that were within the range of those reported in PD patients without 
DBS. Furthermore, neuropathology studies showed no differences in loss of pigmented 
neurons in the substantia nigra of patients with DBS as compared with PD patients without 
DBS.24 There could be several reasons for failure in demonstrating a neuroprotective effect, 
including the lack of appropriate biomarkers of disease progression and the fact that the 
few available studies were conducted in patients with advanced PD.  
Indeed, DBS has traditionally been offered to PD patients at advanced stages of the disease, 
when it is possibly too late to halt neurodegeneration since the pathological processes are 
already too progressed.25 
An important development is the recent trend towards operating at an earlier stage of the 
disease.26 It would be interesting to know whether survival would be more influenced by 
intervening earlier in the disease course. In this respect, the existing RCTs comparing the 
effect of surgery for patients at an earlier stage of the disease with the effect of “best 
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medical treatment”26 may provide important information after a sufficient follow-up. In this 
scenario, patients originally allocated to “best medical treatment” could still be offered DBS 
later in the disease course, allowing detecting a potential effect of a “delayed-onset” of 
neuromodulation and thus revealing important information on this issue.  
In this context it is important to consider that DBS is a burdensome surgical treatment for 
the patients with potential serious, albeit rare, complications. More importantly, especially 
in the long term, DBS offers little or no benefit for non-dopaminergic motor and non-motor 
symptoms, affecting cognitive function, independent locomotion, and communication. 
Notably, these aspects have a predominant influence on quality of life. 
Against the background of the relatively small overall differences in life expectancy between 
PD patients and controls, any ‘true’ difference in survival between operated and non-
operated patients, if existent at all, may be very hard to detect. Nevertheless, even if this 
issue is never fully resolved, it is important to realize that any potentially existent difference 
in survival is clearly outweighed by a considerable improvement in quality of life that 
operated patients experience over an extensive period of time.  
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